Hill-Rom Holdings Inc (NYSE:HRC) – Analysts at Northcoast Research increased their Q2 2018 earnings per share (EPS) estimates for Hill-Rom Holdings in a report issued on Monday. Northcoast Research analyst D. Keiser now expects that the medical technology company will post earnings per share of $1.00 for the quarter, up from their previous forecast of $0.95. Northcoast Research also issued estimates for Hill-Rom Holdings’ Q3 2018 earnings at $1.09 EPS, Q4 2018 earnings at $1.38 EPS, Q1 2019 earnings at $0.91 EPS, Q2 2019 earnings at $1.13 EPS, Q3 2019 earnings at $1.22 EPS, Q4 2019 earnings at $1.53 EPS and FY2019 earnings at $4.80 EPS.

A number of other research firms have also issued reports on HRC. KeyCorp reaffirmed a “buy” rating and issued a $89.00 target price (up previously from $82.00) on shares of Hill-Rom Holdings in a research note on Sunday. Zacks Investment Research raised Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research note on Friday, October 27th. Needham & Company LLC reduced their price target on Hill-Rom Holdings from $93.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday. Stifel Nicolaus reissued a “buy” rating and set a $84.00 price target on shares of Hill-Rom Holdings in a research note on Sunday, July 30th. Finally, BidaskClub raised Hill-Rom Holdings from a “sell” rating to a “hold” rating in a research note on Sunday, August 6th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $88.57.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/07/q2-2018-eps-estimates-for-hill-rom-holdings-inc-hrc-boosted-by-northcoast-research.html.

Hill-Rom Holdings (NYSE HRC) traded up $0.90 during mid-day trading on Tuesday, reaching $78.40. The company had a trading volume of 826,263 shares, compared to its average volume of 495,154. Hill-Rom Holdings has a 12-month low of $50.50 and a 12-month high of $84.65. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. The stock has a market cap of $5,170.00, a price-to-earnings ratio of 20.07, a P/E/G ratio of 1.61 and a beta of 1.19.

Hill-Rom Holdings (NYSE:HRC) last posted its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. During the same quarter in the prior year, the company earned $1.18 EPS. Hill-Rom Holdings’s revenue was up 4.6% on a year-over-year basis.

Institutional investors and hedge funds have recently modified their holdings of the stock. Independent Portfolio Consultants Inc. raised its position in shares of Hill-Rom Holdings by 171.5% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock worth $107,000 after buying an additional 849 shares during the period. Seven Eight Capital LP purchased a new position in shares of Hill-Rom Holdings in the 2nd quarter worth $127,000. Acrospire Investment Management LLC raised its position in shares of Hill-Rom Holdings by 43.4% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock worth $158,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Hill-Rom Holdings by 10.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after buying an additional 204 shares during the period. Finally, Citigroup Inc. raised its position in shares of Hill-Rom Holdings by 21.1% in the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after buying an additional 433 shares during the period. 81.92% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $77.48, for a total value of $532,287.60. Following the transaction, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at approximately $1,293,993.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total value of $306,689.60. Following the completion of the transaction, the senior vice president now directly owns 16,701 shares in the company, valued at $1,300,005.84. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Earnings History and Estimates for Hill-Rom Holdings (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related stocks with our FREE daily email newsletter.